Brought to you by:
Downstream Column | Cell Culture Dish | Agilitech
Future Proofing Bioprocessing from Upstream to Downstream
Case studies on how to implement future-proof bioprocessing systems in a constantly evolving biologics landscape.
Design your bioprocess for now and with flexibility to evolve in the future
The biopharm industry continues to grow at a tremendous rate. This includes innovation into new therapeutic modalities such as novel protein-based therapeutics and gene therapies. These advancements have pushed the industry to evolve to meet continually changing demands and challenges.
In this eBook, industry experts look at current industry trends driving changes in manufacturing and novel solutions to ongoing problems with case study examples. Industry trends include increased use of single-use technologies, shifting demand for manufacturing capacity, the need for flexible manufacturing facilities, and the increased use of automation. The authors examine novel approaches to help evolve biologics manufacturing with future-proof bioprocesses and flexible systems that enable rapid response to changeing priorities, new opporutnities, and increasing demands.
Download this e-book to find the following articles:
Staying Ahead of a Constantly Evolving Biologics Industry
Future Proofing Upstream Bioprocess Operations
Future Proofing Downstream Bioprocess Operations
Upstream and Downstream Processes – A Holistic View
This e-book is brought to you by:
About The Authors
BRANDY SARGENT
Editor-in-chief
Cell Culture Dish & Downstream Column
Brandy Sargent is the Editor in-chief and frequent author of The Cell Culture Dish and The Downstream Column. She has worked in the biotechnology industry for over twenty years, first in corporate communications and public relations, then in technical sales and marketing, and most recently as a writer and publisher. She strives to introduce topics that are interesting, thought provoking, and possible starting points for discussion by the biomanufacturing community. She has been fascinated by the different applications of biotechnology since she first started working in the industry and continues to be fascinated as the industry evolves.
Phil Sanders
Biotech Chief Innovation Officer
Agilitech
Phil Sanders is the Biotech Chief Innovation Officer and Chief Revenue Officer at Agilitech. In his role as Biotech Chief Innovation Officer, Phil leads the company’s quest to deliver state-of-the art technology, engineering and automation services to the biotech industry, supporting the advance of science and medicine to solve health problems and make lives better. Phil has over 30 years of experience in process engineering, automation and systems integration, with specialized expertise in the biotech industry, including related FDA and other regulatory requirements that Agilitech customers must adhere to. Before joining Agilitech, Phil served in senior management positions at both startups and industry-leading companies such as Emerson Impact Partner, Caltrol, and Rockwell Automation.
Dennis Hodgson
Director, Biotech
Agilitech
Dennis Hodgson is Director, Biotech, at Agilitech, providing technical leadership for new product development, as well as custom configurations of Agilitech’s biotech products and systems to meet the unique and specific needs of each client – today and in the future. With over 16 years of engineering/manufacturing experience working at preeminent global companies such as Genentech, Novartis Pharmaceuticals, and Boehringer Ingelheim, Dennis has deep knowledge and experience in all functional areas of bioprocess design and engineering. He also has broad experience with bioprocess system integration, automation and process optimization, and is proficient with multiple market-leading automation platforms such as DeltaV and Rockwell Automation.
